We provide you with 20 years of free, institutional-grade data for IMVT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IMVT. Explore the full financial landscape of IMVT stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-11 | 1764013 | IMVT | 10-Q | Url |
| 2025-05-29 | 1764013 | IMVT | 10-K | Url |
| 2025-02-06 | 1764013 | IMVT | 10-Q | Url |
| 2024-11-07 | 1764013 | IMVT | 10-Q | Url |
| 2024-08-06 | 1764013 | IMVT | 10-Q | Url |
| 2024-05-29 | 1764013 | IMVT | 10-K | Url |
| 2024-02-12 | 1764013 | IMVT | 10-Q | Url |
| 2023-11-09 | 1764013 | IMVT | 10-Q | Url |
| 2023-08-10 | 1764013 | IMVT | 10-Q | Url |
| 2023-05-22 | 1764013 | IMVT | 10-K | Url |
| 2023-02-03 | 1764013 | IMVT | 10-Q | Url |
| 2022-11-04 | 1764013 | IMVT | 10-Q | Url |
| 2022-08-05 | 1764013 | IMVT | 10-Q | Url |
| 2022-06-08 | 1764013 | IMVT | 10-K | Url |
| 2022-02-04 | 1764013 | IMVT | 10-Q | Url |
| 2021-11-05 | 1764013 | IMVT | 10-Q | Url |
| 2021-08-09 | 1764013 | IMVT | 10-Q | Url |
| 2021-06-01 | 1764013 | IMVT | 10-K | Url |
| 2021-02-16 | 1764013 | IMVT | 10-Q | Url |
| 2020-11-12 | 1764013 | IMVT | 10-Q | Url |
| 2020-08-31 | 1764013 | IMVT | S-1 | Url |
| 2020-08-12 | 1764013 | IMVT | 10-Q | Url |
| 2020-06-29 | 1764013 | IMVT | 10-K | Url |
| 2020-04-10 | 1764013 | IMVT | S-1 | Url |
| 2020-02-14 | 1764013 | IMVT | 10-Q | Url |
| 2020-01-17 | 1764013 | IMVT | S-1 | Url |
| 2019-11-13 | 1764013 | IMVT | 10-Q | Url |
| 2019-08-12 | 1764013 | IMVT | 10-Q | Url |
| 2019-06-12 | 1764013 | IMVT | 10-Q | Url |
| 2019-04-16 | 1764013 | IMVT | S-1 | Url |
Immunovant, Inc(NASDAQ:IMVT) 
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phas...
Share this website to your friends
The information provided in this report about IMVT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.